This is compounded by the high failure rate of bringing a new drug to market. A BIO, Biomedtracker market report titled “Clinical Development Success Rates 2006-2015” demonstrated that only 9.64 per cent. of drugs in development reached the market.
N4 Pharma believes that reformulation is an established means by which additional value can be generated by pharmaceutical companies for their brands.
Reformulation of these drugs in-house does not seem to be a priority for most large pharmaceutical companies.
N4 Pharma operates in this niche area, seeking to reformulate selected established drugs by improving their performance, and thereafter licensing the newly reformulated drugs to pharmaceutical companies.